Topic:

R&D

Latest Headlines

Latest Headlines

Little Deciphera raises its cancer R&D flag in Boston's bustling biotech hub

It's not often you find a little biotech company plugging away at new cancer drugs in out-of-the-way places like Lawrence, KS. But that's just what Deciphera Pharmaceuticals has been doing.

Evotec lands two more deals to share risks and rewards of R&D

Germany's Evotec subverts the traditional CRO model by cozying up to its development partners with risk-splitting deals, and the company's approach to R&D has attracted Debiopharm and Convergence Pharmaceuticals with programs in cancer and chronic pain.

Biotech's breathless quarter of IPOs brings in $2.1B for R&D

Back in January, at the annual J.P. Morgan Healthcare Conference, across hotel lobbies and crowded hallways and standing-room-only cafes, one could hardly escape talk about the biotech IPO boom.

Merck vaccine plant taps R&D's Big Data platform to solve yield conundrum

Having invested in data analytics platforms in recent years, pharma R&D labs are working to develop the drugs that will justify their spending. But the experience of Merck suggests the costs can be spread across the business, with manufacturing teams finding the data analytics tools as useful as their peers in R&D do.

Merck and Ferring team up on anti-bleeding drug for the developing world

Alongside Swiss drugmaker Ferring and the World Health Organization, Merck is embarking on a multinational effort to develop an easily transportable treatment for excessive bleeding, hoping to curb global rates of postpartum hemorrhage among the world's poorest mothers.

Amgen's viral cancer vaccine misses its survival goal in melanoma PhIII

After a string of promising late-stage results, Amgen's cancer-fighting viral vaccine failed to extend patients' lives at a statistically significant rate, missing a secondary endpoint and marking the first blemish on the biotech's top cancer prospect.

Halozyme tanks after another mid-stage setback dings its cancer drug

Halozyme has pressed pause on a Phase II trial of its lead cancer candidate over safety concerns, news that sent the biotech's shares down 25% on Friday morning.

Biotronik proceeds with MRI-safe ICD study in the U.S. as initial patients join in

A few weeks after the FDA allowed Biotronik to expand its ProMRI trial to implantable cardioverter-defibrillators, the company hasn't wasted any time moving ahead. The German cardiac device company said it performed initial ICD surgeries for the study at hospitals in Connecticut, Pennsylvania, North Carolina, Michigan, Virginia, New York and Oregon, generally involving its Iforia devices.

Party drug turned 'miracle' cure for depression spurs hype and stubborn hope

The notion that a party drug could be repurposed into a "miracle" cure for severe, treatment-resistant depression is an almost irresistible story line in the popular press. And there's no reason why it can't be recycled using results from the same small, short-duration study design that long ago attracted some of the world's largest research organizations still engaged in researching new drugs in one of the most difficult fields in R&D.

Foundation Medicine teams up with Clovis Oncology to develop ovarian cancer Dx

Foundation Medicine recently revealed plans to raise up to $150 million in a secondary offering to fuel R&D and announced on Thursday that it is teaming up with Clovis Oncology to develop an innovative companion diagnostic for ovarian cancer.